Berman David M
Known title: HEAD OF R&DCIK: 0001955244
Associated companies
Transaction History
| IMCR | ▼ Sell | Open Market | 5,965 | $193K | 2/18/2026 | View on chart |
| IMCR | ▲ Buy | Option Exercise | 11,824 | $0 | 2/17/2026 | View on chart |
| IMCR | ▲ Buy | Option Exercise | 572 | $10K | 12/5/2025 | View on chart |
| IMCR | ▼ Sell | Open Market | 572 | $23K | 12/5/2025 | View on chart |
| IMCR | ▲ Buy | Option Exercise | 31,341 | $547K | 12/4/2025 | View on chart |
| IMCR | ▼ Sell | Open Market | 31,341 | $1.3M | 12/4/2025 | View on chart |
| IMCR | ▲ Buy | Option Exercise | 5,521 | $96K | 11/28/2025 | View on chart |
| IMCR | ▼ Sell | Open Market | 5,521 | $221K | 11/28/2025 | View on chart |
| IMCR | ▲ Buy | Option Exercise | 69,404 | $1.2M | 11/26/2025 | View on chart |
| IMCR | ▼ Sell | Open Market | 69,404 | $2.8M | 11/26/2025 | View on chart |
| IMCR | ▲ Buy | Option Exercise | 18,020 | $315K | 11/25/2025 | View on chart |
| IMCR | ▼ Sell | Open Market | 18,020 | $721K | 11/25/2025 | View on chart |
| IMCR | ▲ Buy | Option Exercise | 100 | $2K | 11/24/2025 | View on chart |
| IMCR | ▼ Sell | Open Market | 100 | $4K | 11/24/2025 | View on chart |
| IMCR | ▼ Sell | Open Market | 61,849 | $2.2M | 9/30/2025 | View on chart |
| IMCR | ▲ Buy | Option Exercise | 61,849 | $1.1M | 9/30/2025 | View on chart |
| IMCR | ▲ Buy | Option Exercise | 200 | $3K | 9/15/2025 | View on chart |
| IMCR | ▼ Sell | Open Market | 200 | $7K | 9/15/2025 | View on chart |
| IMCR | ▲ Buy | Option Exercise | 22,532 | $393K | 9/12/2025 | View on chart |
| IMCR | ▼ Sell | Open Market | 21,232 | $756K | 9/12/2025 | View on chart |
| IMCR | ▼ Sell | Open Market | 1,300 | $47K | 9/12/2025 | View on chart |
| IMCR | ▲ Buy | Option Exercise | 19,081 | $333K | 9/11/2025 | View on chart |
| IMCR | ▼ Sell | Open Market | 19,081 | $692K | 9/11/2025 | View on chart |
| IMCR | ▲ Buy | Option Exercise | 31,338 | $547K | 9/10/2025 | View on chart |
| IMCR | ▼ Sell | Open Market | 1,200 | $44K | 9/10/2025 | View on chart |
| IMCR | ▼ Sell | Open Market | 30,138 | $1.1M | 9/10/2025 | View on chart |
| IMCR | ▼ Sell | Open Market | 7,472 | $514K | 2/28/2024 | View on chart |
| IMCR | ▼ Sell | Open Market | 1,200 | $85K | 2/28/2024 | View on chart |
| IMCR | ▲ Buy | Option Exercise | 36,509 | $637K | 2/28/2024 | View on chart |
| IMCR | ▼ Sell | Open Market | 10,937 | $763K | 2/28/2024 | View on chart |
| IMCR | ▼ Sell | Open Market | 16,900 | $1.1M | 2/28/2024 | View on chart |
| IMCR | ▲ Buy | Option Exercise | 54,938 | $959K | 2/27/2024 | View on chart |
| IMCR | ▼ Sell | Open Market | 3,394 | $244K | 2/27/2024 | View on chart |
| IMCR | ▼ Sell | Open Market | 4,448 | $309K | 2/27/2024 | View on chart |
| IMCR | ▼ Sell | Open Market | 21,152 | $1.5M | 2/27/2024 | View on chart |
| IMCR | ▼ Sell | Open Market | 25,944 | $1.9M | 2/27/2024 | View on chart |
| IMCR | ▲ Buy | Option Exercise | 28,553 | $499K | 2/26/2024 | View on chart |
| IMCR | ▼ Sell | Open Market | 26,516 | $1.9M | 2/26/2024 | View on chart |
| IMCR | ▼ Sell | Open Market | 2,037 | $145K | 2/26/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Immunocore (IMCR) Listed in October Healthcare Watchlist
Immunocore Holdings was included in a Yahoo Finance list of top healthcare stocks to watch in October 2026. This inclusion highlights the company's relevance in the sector, although the stock currently trades near its 52-week low of $27.55. The share price sits close to a key support level at $28.58, while the average analyst target remains significantly higher at $62.73.
Immunocore (IMCR) Listed in October Healthcare Watchlist. Immunocore Holdings was included in a Yahoo Finance list of top healthcare stocks to watch in October 2026. This inclusion highlights the company's relevance in the sector, although the stock currently trades near its 52-week low of $27.55. The share price sits close to a key support level at $28.58, while the average analyst target remains significantly higher at $62.73.